Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.4K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.4K
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

6.3K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
6.3K
Erythropoiesis01:14

Erythropoiesis

6.2K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
6.2K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.0K
Hematopoiesis01:21

Hematopoiesis

9.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.3K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcription of the human U2 snRNA genes continues beyond the 3' box in vivo.

The EMBO journal·1999
Same author

Exposure to traumatic incidents and prevalence of posttraumatic stress symptomatology in urban firefighters in two countries.

Journal of occupational health psychology·1999
Same author

The effect of keeping an end-product on intrinsic motivation.

The American journal of occupational therapy : official publication of the American Occupational Therapy Association·1999
Same author

Transcriptional activation following cerebral ischemia in mice of a promoter-deleted nitric oxide synthase-2 gene.

The Journal of biological chemistry·1999
Same author

Transmission electron microscopy studies of Moraxella (Branhamella) catarrhalis.

FEMS immunology and medical microbiology·1999
Same author

Consultation with the specialist. Thrombocytopenia.

Pediatrics in review·1999
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

1.0K

Polycythemia vera.

S Murphy1

  • 1Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.

Disease-A-Month : DM
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Polycythemia vera (PV) is a myeloproliferative neoplasm causing overproduction of red blood cells, often with increased white blood cells and platelets. Diagnosis involves excluding other polycythemic conditions and confirming increased red cell mass.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K

Related Experiment Videos

Last Updated: Feb 24, 2026

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

1.0K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.5K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

2.0K

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Polycythemia vera (PV) is a clonal myeloproliferative neoplasm characterized by the overproduction of red blood cells.
  • It arises from a single abnormal hematopoietic stem cell with a growth advantage.
  • Symptoms include nonspecific signs of increased red cell mass and specific manifestations like pruritus and thrombosis.

Purpose of the Study:

  • To provide a comprehensive overview of Polycythemia vera (PV).
  • To discuss diagnostic criteria, differentiating PV from other polycythemic states.
  • To outline current therapeutic strategies and their associated risks and benefits.

Main Methods:

  • Review of clinical presentation and laboratory findings in PV.
  • Discussion of diagnostic approaches, including exclusion of spurious and secondary polycythemia.
  • Analysis of therapeutic options: phlebotomy, plateletpheresis, myelosuppressive agents (hydroxyurea), and antiplatelet agents.

Main Results:

  • The hallmark of PV is an increased red cell mass, often accompanied by elevated white blood cell and platelet counts.
  • Bone marrow biopsy typically shows hypercellularity and absent iron stores.
  • Therapeutic choices impact morbidity and mortality, with phlebotomy alone increasing thrombotic risk and myelosuppressive therapy linked to secondary malignancies.

Conclusions:

  • Accurate diagnosis of PV requires excluding other causes of polycythemia and confirming increased red cell mass through various studies.
  • Chronic management involves balancing the risks of thrombotic complications with those of myelosuppressive therapies.
  • Median survival is approximately 10 years, with potential progression to spent phase and postpolycythemic myeloid metaplasia.